BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 37449556)

  • 1. Mediators and mechanisms of immune checkpoint inhibitor-associated myocarditis: Insights from mouse and human.
    Gong J; Neilan TG; Zlotoff DA
    Immunol Rev; 2023 Sep; 318(1):70-80. PubMed ID: 37449556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Responses in Checkpoint Myocarditis Across Heart, Blood, and Tumor.
    Blum SM; Zlotoff DA; Smith NP; Kernin IJ; Ramesh S; Zubiri L; Caplin J; Samanta N; Martin SC; Tirard A; Sen P; Song Y; Barth J; Slowikowski K; Nasrallah M; Tantivit J; Manakongtreecheep K; Arnold BY; McGuire J; Pinto CJ; McLoughlin D; Jackson M; Chan P; Lawless A; Sharova T; Nieman LT; Gainor JF; Juric D; Mino-Kenudsen M; Sullivan RJ; Boland GM; Stone JR; Thomas MF; Neilan TG; Reynolds KL; Villani AC
    bioRxiv; 2023 Nov; ():. PubMed ID: 37790460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis.
    Zhu H; Galdos FX; Lee D; Waliany S; Huang YV; Ryan J; Dang K; Neal JW; Wakelee HA; Reddy SA; Srinivas S; Lin LL; Witteles RM; Maecker HT; Davis MM; Nguyen PK; Wu SM
    Circulation; 2022 Jul; 146(4):316-335. PubMed ID: 35762356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study.
    Xie X; Wang L; Li Y; Xu Y; Wu J; Lin X; Lin W; Mai Q; Chen Z; Zhang J; Xie Z; Qin Y; Liu M; Lu M; Luo B; Zhou C
    Front Immunol; 2022; 13():879900. PubMed ID: 35924238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis.
    Won T; Kalinoski HM; Wood MK; Hughes DM; Jaime CM; Delgado P; Talor MV; Lasrado N; Reddy J; Čiháková D
    Cell Rep; 2022 Nov; 41(6):111611. PubMed ID: 36351411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms.
    Moslehi J; Lichtman AH; Sharpe AH; Galluzzi L; Kitsis RN
    J Clin Invest; 2021 Mar; 131(5):. PubMed ID: 33645548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiotoxicity of Immune Checkpoint Inhibitors.
    Patel RP; Parikh R; Gunturu KS; Tariq RZ; Dani SS; Ganatra S; Nohria A
    Curr Oncol Rep; 2021 May; 23(7):79. PubMed ID: 33937956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ANGPTL2 promotes immune checkpoint inhibitor-related murine autoimmune myocarditis.
    Horiguchi H; Kadomatsu T; Yamashita T; Yumoto S; Terada K; Sato M; Morinaga J; Miyata K; Oike Y
    Commun Biol; 2023 Sep; 6(1):965. PubMed ID: 37736764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Research Progress of Immune Checkpoint Inhibitor-associated Myocarditis].
    Liu Y; Chen Y; Zeng Z; Liu A
    Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):668-672. PubMed ID: 34521189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk Factors for Immune Checkpoint Inhibitor-Mediated Cardiovascular Toxicities.
    Yousif LI; Screever EM; Versluis D; Aboumsallem JP; Nierkens S; Manintveld OC; de Boer RA; Meijers WC
    Curr Oncol Rep; 2023 Jul; 25(7):753-763. PubMed ID: 37079251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heart-Specific Immune Responses in an Animal Model of Autoimmune-Related Myocarditis Mitigated by an Immunoproteasome Inhibitor and Genetic Ablation.
    Bockstahler M; Fischer A; Goetzke CC; Neumaier HL; Sauter M; Kespohl M; Müller AM; Meckes C; Salbach C; Schenk M; Heuser A; Landmesser U; Weiner J; Meder B; Lehmann L; Kratzer A; Klingel K; Katus HA; Kaya Z; Beling A
    Circulation; 2020 Jun; 141(23):1885-1902. PubMed ID: 32160764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNF-α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis.
    Liu X; Wu W; Fang L; Liu Y; Chen W
    Front Immunol; 2022; 13():922782. PubMed ID: 35844550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity.
    Guo X; Wang H; Zhou J; Li Y; Duan L; Si X; Zhang L; Fang L; Zhang L
    Thorac Cancer; 2020 Feb; 11(2):475-480. PubMed ID: 31849171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program.
    Naqash AR; Moey MYY; Cherie Tan XW; Laharwal M; Hill V; Moka N; Finnigan S; Murray J; Johnson DB; Moslehi JJ; Sharon E
    J Clin Oncol; 2022 Oct; 40(29):3439-3452. PubMed ID: 35658474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors.
    Esposito R; Fedele T; Orefice S; Cuomo V; Prastaro M; Canonico ME; Ilardi F; De Stefano F; Fiorillo L; Santoro C; Esposito G
    Biomolecules; 2021 May; 11(6):. PubMed ID: 34067474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cells specific for α-myosin drive immunotherapy-related myocarditis.
    Axelrod ML; Meijers WC; Screever EM; Qin J; Carroll MG; Sun X; Tannous E; Zhang Y; Sugiura A; Taylor BC; Hanna A; Zhang S; Amancherla K; Tai W; Wright JJ; Wei SC; Opalenik SR; Toren AL; Rathmell JC; Ferrell PB; Phillips EJ; Mallal S; Johnson DB; Allison JP; Moslehi JJ; Balko JM
    Nature; 2022 Nov; 611(7937):818-826. PubMed ID: 36385524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of subclinical immune checkpoint inhibitor-associated myocarditis in non-small cell lung cancer.
    Hu Y; Liu C; Jin S; Yi Z; Wang C; Pan X; Huang H
    BMC Pulm Med; 2023 Apr; 23(1):119. PubMed ID: 37060029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effect of low-intensity pulsed ultrasound on immune checkpoint inhibitor-related myocarditis via fine-tuning CD4
    Fu S; Guo Z; Xu X; Li Y; Choi S; Zhao P; Shen W; Gao F; Wang C; Chen S; Li Y; Tian J; Sun P
    Cancer Immunol Immunother; 2024 Jan; 73(1):15. PubMed ID: 38236243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitors Mediated Lymphocytic and Giant Cell Myocarditis: Uncovering Etiological Mechanisms.
    Rikhi R; Karnuta J; Hussain M; Collier P; Funchain P; Tang WHW; Chan TA; Moudgil R
    Front Cardiovasc Med; 2021; 8():721333. PubMed ID: 34434981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series.
    Coustal C; Vanoverschelde J; Quantin X; Lesage C; Michot JM; Lappara A; Ederhy S; Assenat E; Faure M; Issa N; Lambotte O; Puyade M; Dereure O; Tosi D; Rullier P; Serre I; Larcher R; Klouche K; Chanques G; Vernhet-Kovacsik H; Faillie JL; Agullo A; Roubille F; Guilpain P; Maria ATJ
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.